Zhou Bohuai, Chen Qiuyu, Zhang Qiuwen, Tian Weidong, Chen Tian, Liu Zhi
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Engineering Research Center of Oral Translational Medicine, Ministry of Education & National Engineering Laboratory for Oral Regenerative Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China.
Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China.
Stem Cell Res Ther. 2024 Aug 7;15(1):249. doi: 10.1186/s13287-024-03863-5.
Inflammation is a key pathological feature of many diseases, disrupting normal tissue structure and resulting in irreversible damage. Despite the need for effective inflammation control, current treatments, including stem cell therapies, remain insufficient. Recently, extracellular vesicles secreted by adipose-derived stem cells (ADSC-EVs) have garnered attention for their significant anti-inflammatory properties. As carriers of bioactive substances, these vesicles have demonstrated potent capabilities in modulating inflammation and promoting tissue repair in conditions such as rheumatoid arthritis, osteoarthritis, diabetes, cardiovascular diseases, stroke, and wound healing. Consequently, ADSC-EVs are emerging as promising alternatives to conventional ADSC-based therapies, offering advantages such as reduced risk of immune rejection, enhanced stability, and ease of storage and handling. However, the specific mechanisms by which ADSC-EVs regulate inflammation under pathological conditions are not fully understood. This review discusses the role of ADSC-EVs in inflammation control, their impact on disease prognosis, and their potential to promote tissue repair. Additionally, it provides insights into future clinical research focused on ADSC-EV therapies for inflammatory diseases, which overcome some limitations associated with cell-based therapies.
炎症是许多疾病的关键病理特征,会破坏正常组织结构并导致不可逆损伤。尽管需要有效控制炎症,但包括干细胞疗法在内的当前治疗方法仍然不足。最近,脂肪来源干细胞分泌的细胞外囊泡(ADSC-EVs)因其显著的抗炎特性而受到关注。作为生物活性物质的载体,这些囊泡在类风湿性关节炎、骨关节炎、糖尿病、心血管疾病、中风和伤口愈合等病症中已显示出在调节炎症和促进组织修复方面的强大能力。因此,ADSC-EVs正成为传统基于ADSC疗法的有前途的替代方案,具有降低免疫排斥风险、增强稳定性以及易于储存和处理等优势。然而,ADSC-EVs在病理条件下调节炎症的具体机制尚未完全了解。本综述讨论了ADSC-EVs在炎症控制中的作用、它们对疾病预后的影响以及它们促进组织修复的潜力。此外,它还为未来针对炎症性疾病的ADSC-EV疗法的临床研究提供了见解,该疗法克服了一些与基于细胞的疗法相关的局限性。